Single Ascending and Multiple Ascending Dose Study of LCA-0061

Summary

This is a Phase 1combined single ascending dose (SAD)/multiple ascending dose (MAD) randomized, double-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of LCA-0061in participants with atopic conditions (SAD) and participants with peanut allergy (MAD).

Timeline

Start

2026-06-26

Primary completion

2028-04

Completion

2028-04

Drugs

Indications